The company today announced that preclinical data on one of its IDO pathway inhibitors, NLG919, will be presented at the 2013 Annual Meeting of the American Association for Cancer Research to be held 1:00 -5:00 PM, "NLG919, a novel indoleamine-2,3-dioxygenase -pathway inhibitor drug candidate for cancer therapy," M. IDO pathway inhibitors are ... (more)
http://www.macreportmedia.com/ViewSubmission.aspx?submissionRequest=22099
http://www.macreportmedia.com/ViewSubmission.aspx?submissionRequest=22099
No comments:
Post a Comment